The news directly pertains to ACADIA Pharmaceuticals as the analyst reiterates a Neutral rating and maintains a $20 price target. This indicates that the analyst believes the stock is fairly valued and does not expect significant price movement in the short term. As a result, the short-term impact on the stock price is neutral.